ANRS 177 DUETTO
Randomised, multicentre, national, open-label trial evaluating the non-inferiority of antiretroviral dual therapy taken on 4 consecutive days per week versus antiretroviral dual therapy taken continuously, in HIV-1 infected patients with controlled viral load under antiretroviral dual therapy
Last updated on 27 February 2024
Primary objective
To evaluate at Week 48 the non-inferiority of antiretroviral dual therapy Dolutegravir/Lamivudine or Dolutegravir/Rilpivirine or Darunavir/r/Lamivudine taken 4 consecutive days a week versus dual therapy taken 7 days a week in HIV patients with therapeutic success on antiretroviral dual therapy (viral load<50 copies/mL).
Theme
VIH
Population
Adults
Status
Ongoing
Samples
DNA, RNA, Plasma, total Blood
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr